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Oral Presentations 1746 years (range 1–71)] between 10/05-5/08 with the hypothesis that
CB would extend transplant access. Adequate donor-recipient HLA-
match was $8/10 HLA-A,B,C,DRB1,DQ alleles for a T cell de-
pleted or $9/10 alleles for an unmodified URD graft. Adequate
CB units were $4/6 HLA-A,B antigen, DRB1 allele matched &
$1.5 107 TNC/kg/unit. Double unit grafts were used to augment
engraftment. URDs had priority; CB was chosen if no suitable URD
was available in the required time period. The 309 patients had
highly diverse ancestry with only 68 (22%) of northwest (NW) Eu-
ropean & 108 (35%) of non-European origin. The ancestry of 201
transplanted patients & the 15 not transplanted due to lack of suit-
able graft is shown below. The remaining 93 patients were not trans-
planted for other reasons. URD transplant recipients were
predominantly NW (32%), eastern (18%) or mixed (18%) European
with Asian, African & Hispanic patients combined accounting for
only 18%. In contrast, only 4 (8%) of CBT recipients were NW
European. While these patients received CB due to urgency (n 5
1), patient preference (n 5 1), or MD preference over mismatched
URD (n 5 2), the remaining 48 (92%) of CBT recipients including
15% Southern Europeans and 49% non-Europeans (13% Asian,
19% African, 15% Hispanic, 2% Middle Eastern) had no URD op-
tion. Of 15 patients not transplanted due to lack of any HSC source
10 were non-European including 6 of African ancestry. Their me-
dian weight [87kg (range 66–151)] was significantly higher than
CBT recipients [70kg (range 13–109); p\0.01] partially accounting
for their lack of suitable CB grafts. Thus, URD transplantation pre-
dominantly serves patients of NW, Eastern & mixed European an-
cestry with many Southern & non-Europeans having no suitable
URD. In contrast, CB significantly extends transplant access to all
but especially to both Southern & non-Europeans. Patients of
African ancestry are the most challenged to secure a suitable graft.
This data is compelling support for increased funding of public
CB banking & suggests that CB has the greatest potential to fulfill
the promise of being able to offer allograft to all regardless of race.
Patient Ancestry if Transplanted or No Graft
8-10/10 URD (n5149) 4-6/6 CB (n552) No graft (n515)NW Europe 47 (32%) 4 (8%) 1 (7%)
East Europe 27 (18%) 6 (12%) 0 (0%)
South Europe 15 (10%) 8 (15%) 3 (20%)
Mix: Europe 27 (18%) 8 (15%) 1 (7%)
Asian 6 (4%) 7 (13%) 0 (0%)
African 11 (7%) 10 (19%) 6 (40%)
Hispanic 10 (7%) 8 (15%) 3 (20%)
Middle East 5 (3%) 1 (2%) 0 (0%)
Mix: Non-Europe 1 (1%) 0 (0%) 1 (7%)*Significantly different (p#0.05).39
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Washing of CB after thawing prior to infusion into patients (pts)
is an accepted practice in CB transplantation. The potential clinical
benefits were extrapolated from early in vitro studies using units
processed by RBC reduction (RCR) with hetastarch. Other proce-
dures for processing (PD, RCR using gelatin or buffy coat) have
produced equally high quality CB with similar clinical outcome.
In this report, we analyzed the impact of post-thaw washing (W)
on clinical outcome using PD CB. A total of 487 PD CB was in-
fused into 434 pts with malignant or non-malignant diseases.
The decision to wash (222 pts) or not to wash (NW) CB after
thawing was at the discretion of individual transplant centers. Pt
matching was used to compare the W and NW cohorts. Pts wereassigned propensity scores based on age, weight, number of infused
CB, total nucleated cell (NC) dose, and HLA mismatches, then
each pt in the NW group was assigned a pt in the W group with
the nearest score to form a pair, allowing us to form a group of
129 W pts with the same diagnoses as those in a group of 129
NW pts. Outcome parameters including cumulative incidence
(CI) and days to ANC 500 and platelet 20k engraftment, grade
III-IV acute graft-versus-host-disease (aGvHD), extensive chronic
graft-versus-host-disease (cGVHD), 100-day and 1-year transplant
related mortality (TRM), 1-year relapse rate, OS and DFS, were
summarized in the table below. The analyses confirm that pts re-
ceiving NW CB have similar (aGvHD, relapse) or superior clinical
outcomes (ANC and platelet engraftment, cGVHD, TRM, OS and
DFS) to those receiving W units. It should be pointed out that
although the 100-day TRM appeared similar, the 1-year TRM
diverged significantly for the 2 groups. Pts receiving NW CB
had higher incidences of limited cGvHD but lower incidences of
extensive cGvHD as compared to those receiving W CB. Despite
this reduction in the severity and lower cumulative incidence of ex-
tensive cGvHD, pts receiving NW and W PD CB have similar re-
lapse rates, suggesting that Graft-versus-Leukemia effects may not
be compromised in the NW group. These observations also sug-
gest there may be a potential immunomodulatory mechanism
whereby the severity of cGvHD is reduced, which may contribute
to improved survival. In conclusion, our results suggest that post-
thaw washing of PD CB may be associated with poorer clinical out-
comes and prospective investigation on the effect of washing on
post CB transplant management may be warranted.
Impact of post-thaw washing of PD CB — All patients
Gr TRM*ANC
500* (d)Plt
20k* (d)III-IV
aGvHDExtensive
cGvHD*100
d/1 yr Relapse OS*/DFS*Washed 8564%
(27)6364%
(55)1563% 1663% 1863%/3464% 3165% 5464%/
4664%Unwashed 8665%
(20.5)7765%
(45)1763% 462% 1663%/2263% 2365% 6963%/
6264%Impact of post-thaw washing of PD CB — Matched PairsANC
500*
(d)Plt 20k*
(d)Gr III-IV
aGvHDExtensive
cGvHD*TRM* 100
d/1 yrRelapse OS*/
DFS*Washed 8366%
(28)5866%
(56.5)1463% 1764% 2164%/4165% 2866% 4865%/
4365%Unwashed 8966%
(21)7867%
(45)1464% 462% 1463%/2164% 2466% 6964%/
6165%40
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The naive phenotype of cord blood (CB) cells contributes to the
lower incidence and reduced severity of GvHD after umbilical cord
blood transplant (CBT). However, the relatively low cell numbers
and naivety of T-cell populations in CB grafts has lead to delayed im-
mune reconstitution and higher mortality due to infection. CMV and
adenovirus (Adv) are particularly problematic infections in patients af-
ter CBT. Previous studies have shown that adoptive immunotherapy
with peripheral blood-derived CTL directed against CMV and Adv
can effectively prevent the clinical manifestations of these viruses after
HSCT suggesting that a similar approach could be developed after
CBT. We hypothesized that CTL could be generated from CB for
clinical use to restore anti-viral immunity and reduce viral infection
post CBT. 40 106 CB mononuclear cells (available in the 20% frac-
tion of frozen CB units) were thawed and used for generation of bi-vi-
rus specific CTL. A clinical-grade recombinant Adv type 5 vector
pseudotyped with a type35 fiber carrying a transgene for CMVpp65
